ArticleGut2013
The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.
Article in Gut, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03231332 (Long Term Effects of H.Pylori Eradication on Microbiome and Adverse Events), which is not on this map. Cited by 150 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long Term Effects of H.Pylori Eradication on Microbiome and Adverse Events
Who cites it
150 citing papers in PubMed, 14 syntheses or guidelines pooled it, 342 citations in OpenAlex.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors.Gastroenterology · 2020Pooled it
- AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes.Gastroenterology · 2020Pooled it
- Advancing the Science in Gastric Pre-Neoplasia: Study Design Considerations.Gastroenterology · 2020Pooled it
- Risk factors of perioperative mortality from complicated peptic ulcer disease in Africa: systematic review and meta-analysis.BMJ open gastroenterology · 2020Pooled it
- Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Pooled it
- Association Between Anti-bacterial Drug Use and Digestive System Neoplasms: A Systematic Review and Meta-analysis.Frontiers in oncology · 2019Pooled it
- Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Pooled it
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2014Pooled it
- Trial
- The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy forAnnals of medicine · 2022Trial
- Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial.Scientific reports · 2022Trial
- The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.Gastroenterology · 2021Trial
- Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.Frontiers of medicine · 2020Trial
- Effects ofBMJ (Clinical research ed.) · 2019Trial
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the benefit of mass eradication of Helicobacter pylori infection in reducing premalignant gastric lesions.
designMass eradication of H pylori infection was started from 2004 for a Taiwanese population with prevalent H pylori infection, who were >30 years of age. Participants positive for the (13)C-urea breath test underwent endoscopic screening and 1-week clarithromycin-based triple therapy. For subjects whose initial treatment failed, 10-day levofloxacin-based triple therapy was administered. The main outcome measures were changes in the prevalence of H pylori infection and premalignant gastric lesions, and changes in the incidence of premalignant gastric lesions and gastric cancer before (1995-2003) and after (2004-2008) chemoprevention using various comparators.
resultsThe reduction in H pylori infection was 78.7% (95% CI 76.8% to 80.7%), and the estimated incidence of re-infection/recrudescence was 1% (95% CI 0.6% to 1.4%) per person-year. The effectiveness of reducing the incidence of gastric atrophy resulting from chemoprevention was significant at 77.2% (95% CI 72.3% to 81.2%), while the reduction in intestinal metaplasia was not significant. Compared with the 5-year period before chemoprevention and in the absence of endoscopic screening, the effectiveness in reducing gastric cancer incidence during the chemoprevention period was 25% (rate ratio 0.753, 95% CI 0.372 to 1.524). The reduction in peptic ulcer disease was 67.4% (95% CI 52.2% to 77.8%), while the incidence of oesophagitis was 6% (95% CI 5.1% to 6.9%) after treatment.
conclusionsPopulation-based eradication of H pylori infection has led to a significant reduction in gastric atrophy at the expense of increased oesophagitis. The ultimate benefit in reducing gastric cancer incidence and its mortality should be validated by a further long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.